Results 31 to 40 of about 35,072 (188)

Protective Effect of Adalimumab on Diabetic Nephropathy by Regulating TNF-α Signal Pathway

Iranian Journal of Public Health, 2021
Background: To evaluate the inhibitory effect of adalimumab on diabetic nephropathyDN) through animal models. Methods: We carried out the study in Weifang People’s Hospital, Weifang 261041, China in December 2020.
Zhiying Ding, Hongxia Jiang, Yongsong Fan, Guiqin Sun   +3 more
doaj   +1 more source

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis

Pifu-xingbing zhenliaoxue zazhi, 2023
Objective To evaluate the efficacy and safety of Secukinumab versus Adalimumab in the treatment of the moderate to severe plaque psoriasis. Methods A total of 90 patients with moderate to severe psoriasis were randomly divided into three groups ...
Dandan HU, Peimiao ZHANG
doaj   +1 more source

Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Pediatric Rheumatology Online Journal, 2023
Background Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU ...
Jo L. Dehoorne, Helena Groth, Emma Carlé, Ilse De Schrijver, Celine Sys, Patricia Delbeke, Elke O. Kreps, Thomas Renson, Carolien Bonroy   +8 more
doaj   +1 more source

Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial

Journal of American Academy of Dermatology, 2017
Background: Guselkumab, an interleukin‐23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. Objectives: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with ...
A. Blauvelt, K. Papp, C. Griffiths, B. Randazzo, Y. Wasfi, Yaung-Kaung Shen, Shu Li, A. Kimball   +7 more
semanticscholar   +1 more source

Adalimumab in Psoriatic Arthritis

The Journal of Rheumatology Supplement, 2012
Open prospective studies and randomized controlled trials (RCT) have shown the short-term efficacy of adalimumab (ADA) in psoriatic arthritis (PsA) and psoriasis. ADA effectively treated all varied musculoskeletal manifestations characteristic of PsA, including peripheral arthritis, spinal disease, enthesitis, and dactylitis.
SALVARANI, CARLO, Pipitone, Nicolò, Catanoso, Mariagrazia, Chiarolanza, Ilaria, Boiardi, Luigi, Caruso, Andrea, Pazzola, Giulia, Macchioni, Pierluigi, Di Lernia, Vito, Albertini, Giuseppe   +9 more
openaire   +4 more sources

Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study

Journal of gastroenterology, 2021
This multicenter prospective study (UMIN000019958) aimed to evaluate the usefulness of serum leucin-rich alpha-2 glycoprotein (LRG) levels in monitoring disease activity in inflammatory bowel disease (IBD).
S. Shinzaki, K. Matsuoka, Hiroki Tanaka, F. Takeshima, S. Kato, T. Torisu, Yuki Ohta, Kenji Watanabe, Shiro Nakamura, N. Yoshimura, Taku Kobayashi, A. Shiotani, Fumihito Hirai, S. Hiraoka, Mamoru Watanabe, M. Matsuura, Shohei Nishimoto, S. Mizuno, H. Iijima, T. Takehara, T. Naka, T. Kanai, T. Matsumoto   +22 more
semanticscholar   +1 more source

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis

Pediatric Rheumatology Online Journal, 2023
Background Adalimumab in combination with other disease-modifying antirheumatic drugs (DMARD) such as methotrexate has a proven efficacy in the management of paediatric non-infectious uveitis.
DA Al-Julandani, NK Bagri, N Tsang, S Clarke, A Upadhyay, C Guly, AV Ramanan   +6 more
doaj   +1 more source

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial

Trials, 2020
Background Juvenile idiopathic arthritis (JIA)-associated uveitis is a chronic paediatric ocular inflammatory condition that can result in visual impairment.
Nisha R. Acharya, Caleb D. Ebert, Nicole K. Kelly, Travis C. Porco, Athimalaipet V. Ramanan, Benjamin F. Arnold, the ADJUST Research Group   +6 more
doaj   +1 more source

The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy

Annals of Saudi Medicine, 2021
BACKGROUND: Adalimumab is a fully humanized monoclonal antibody inhibitor of tumor necrosis factor-a used to treat various autoimmune disorders. Adalimumab poses a risk for tuberculosis (TB) infection, especially in countries where TB is endemic ...
Abdullah Al-Sohaim, Abdullah Saleh Bawazir, Turki Al-Turki, Eiman Omar Alsafi, Abdullah Al-Roqy, Layla Layqah, Salim Alawi Baharoone   +6 more
doaj   +1 more source

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial

Dermatology Practical & Conceptual, 2022
Introduction The randomized, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology ...
K. Reich, L. Kristensen, Saxon D. Smith, P. Rich, C. Sapin, S. L. Leage, R. Mckenzie, C. Schuster, E. Riedl, M. Gooderham   +9 more
semanticscholar   +1 more source